Inozyme Pharma falls on CEO retirement

Inozyme Pharma

22/03/2023 14:47

** Shares of rare disease therapy developer Inozyme Pharma
 INZY.O  down as much as 4.9% at $2.89
    ** Co says founding CEO Axel Bolte will retire from his role
 urn:newsml:reuters.com:*:nTUA31KGBR 
    ** Adds chairman of board Douglas A. Treco will succeed
Bolte as CEO, effective April 1 
    ** Co also posts FY loss per share of $1.78 vs loss of $2.40
a year earlier 
    ** Including session losses, INZY stock has surged 175% YTD 

 (Reporting by Amna Karimi in Bengaluru)
 ((Amna.Karimi@thomsonreuters.com; +91 8083261226;))